2017 American Transplant Congress
De Novo Donor-Specific Antibody Formation After Kidney Retransplant Is Associated with Specificity Against Class I.
Retransplant (RTx) patients are often sensitized due to donor-specific antibody (DSA) formation, with higher acute rejection rates during subsequent transplants vs patients without DSA. However,…2017 American Transplant Congress
Pre Transplant Donor Specific Antibodies and Clinical Outcomes in Kidney Transplant Recipient on Steroid Free Maintenance Immunosupression Regimen.
Background: The clinical relevance of pre transplant donor specific antibodies has been reported in few clinical studies with respect to its effect on the risk…2017 American Transplant Congress
Higher Tacrolimus Blood Levels Predict Better Graft Survival in Kidney Recipients with De Novo DSA.
Background: De novo anti-HLA donor specific antibodies (dnDSA) are associated with poorer outcomes in kidney transplant recipients. Nonetheless, their monitoring post transplant is not widespread,…2017 American Transplant Congress
Microcirculation Inflammation in Kidney Allograft Biopsies.
Introduction: The Microcirculation Inflammation (IM) in kidney transplants is a strong predictor of graft loss inde-pedent of C4d and donor specific antibody(DSA)ObjetiveAnalysis of kidney allograft…2017 American Transplant Congress
A Phase Ib, Open Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients with End-Stage Renal Disease.
1U.Cincinnati, OH; 2Prolong Pharmaceuticals, NJ
Purpose:The endeavor and resources spent to study desensitization haven't been matched by an effort to investigate strategies to prevent sensitization.The purpose of this study was…2017 American Transplant Congress
Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome.
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well determined. We have validated the institutional…2017 American Transplant Congress
Tacrolimus Appears to Be a Protective Factor for De Novo DSA Formation in Non-Sensitized Kidney Transplant Patients.
Background.Development of de novo donor specific antibodies (dnDSA) concerns about 10% of patients within the first year following kidney transplantation and reach about 20% within…2017 American Transplant Congress
De Novo DSA with T Cell Mediated Rejection (TCMR) Leads to Early Allograft Scarring and Dysfunction.
Detection of de novo DSA is associated with adverse outcomes in kidney transplant recipients (KTRs). The relationship between de novo DSA and subsequent TCMR and…2017 American Transplant Congress
Banff 2013 Classification of Renal Allograft Pathology Is Superior to Banff 2007 in Detecting and Managing Milder and Earlier Cases of Antibody-Mediated Rejection.
The 2013 Banff meeting updated the requirements for the diagnosis of acute/active antibody-mediated rejection (AAMR) in kidney allografts. There has been speculation that the changes…2017 American Transplant Congress
Continuation of Immunosuppression Appears to Protect Against Allosensitization in Patients Listed for a Second Kidney Transplant.
Purpose: The current standard of practice after allograft loss is to discontinue immunosuppression (IS) to decrease complications related to prolonged exposure. There is a paucity…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 40
- Next Page »